Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Lapatinib in Combination With Weekly Topotecan in Patients With Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma

NCT00436644 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00436644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00436644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Lapatinib in Combination With Weekly Topotecan in Patients With Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
November 30, 2012
Enrollment
18 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, peritoneal cavity cancer